Medimaging Integrated Solution, an innovative smart medical technology company, announced that its revenue in December 2024 surged to NT$116 million, marking a record monthly high. This represents an over twofold increase compared to both the previous month and the same period last year, driving the company’s annual revenue to a new peak. Looking ahead to 2025, the company’s multiple growth engines are set to further boost its performance. These include the official Q1 shipment of its disposable cystoscope, licensed to Boston Scientific (NYSE: BSX); ongoing commercial contract discussions for its disposable bronchoscope with the largest emergency medical services company in the U.S.; and a newly signed distribution agreement for veterinary use with a renowned publicly listed Japanese medical device company. With these developments, the company anticipates strong double-digit growth in 2025.
In December 2024, Medimaging Integrated Solution achieved a revenue of NT$116 million, reflecting a 132.3% month-over-month increase and a 118.7% year-over-year growth. Annual revenue reached NT$539 million, marking a 0.32% increase and the highest level in five years. The December revenue surge was primarily driven by the fulfillment of a large order for its digital endoscope series, which had previously faced supply chain constraints.
The disposable cystoscope, licensed to global medical device leader Boston Scientific, is set for official shipment in Q1 2025. The company has expanded its regulatory approval plan from 18 countries to 24, aligning with Boston Scientific’s global certification efforts. Medimaging Integrated Solution stated that its licensing partner aims to promote the product worldwide, with European MDR Class II certification expected shortly. While shipments will commence in Q1, significant contributions to revenue are anticipated starting in Q2.
For the disposable bronchoscope, the company is currently negotiating commercial contract details with the largest emergency medical services provider in the U.S., specializing in emergency and anesthesiology. Clinical trials, product demonstrations, and promotions in hospitals are expected to begin this year. Additionally, a distribution agreement for veterinary applications has been signed with a well-known Japanese medical device company. The product, suitable for general-purpose use across multiple fields, has already been promoted in Japan, with mass production and shipments commencing in December 2024.
Looking ahead to 2025, the market recovery of the flagship digital endoscope series, combined with the official launch of the disposable cystoscope, contributions from the veterinary application of the disposable bronchoscope, and the finalization of the U.S. distribution partnership, are expected to drive significant revenue growth. With multiple engines powering expansion, Medimaging Integrated Solution is on track to achieve robust double-digit revenue growth in 2025.
Resource: 晉弘12月營收暴增一倍創新高，多引擎拉動今年業績跨大步拚增雙位數
